Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in non-small cell lung cancer. by Baratelli, Felicita et al.
UCLA
UCLA Previously Published Works
Title
Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for 
application in a phase I trial in non-small cell lung cancer.
Permalink
https://escholarship.org/uc/item/5097c6gw
Journal
Journal of translational medicine, 6(1)
ISSN
1479-5876
Authors
Baratelli, Felicita
Takedatsu, Hiroko
Hazra, Saswati
et al.
Publication Date
2008-07-22
DOI
10.1186/1479-5876-6-38
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
BioMed CentralJournal of Translational Medicine
ssOpen AcceResearch
Pre-clinical characterization of GMP grade CCL21-gene modified 
dendritic cells for application in a phase I trial in Non-Small Cell 
Lung Cancer
Felicita Baratelli†1, Hiroko Takedatsu†1, Saswati Hazra1, Katherine Peebles1, 
Jie Luo1, Pam S Kurimoto1, Gang Zeng4, Raj K Batra1,3, Sherven Sharma1,3, 
Steven M Dubinett1,2,3 and Jay M Lee*1,5
Address: 1UCLA Lung Cancer Research Program of the Jonsson Comprehensive Cancer Center, Division of Pulmonary and Critical Care Medicine, 
Department of Medicine, Los Angeles, CA 90095, USA, 2Department of Pathology and Laboratory Medicine, Geffen School of Medicine at UCLA, 
Los Angeles, CA, 90095, USA, 3Molecular Medicine Laboratory, Veteran's Affairs Greater Los Angeles Healthcare System, Los Angeles, CA 90073, 
USA, 4Department of Urology, Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA and 5Division of Cardiothoracic Surgery, 
Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
Email: Felicita Baratelli - fbaratelli@mednet.ucla.edu; Hiroko Takedatsu - htakedatsu@mednet.ucla.edu; 
Saswati Hazra - shazra@mednet.ucla.edu; Katherine Peebles - katherine.peebles@gmail.com; Jie Luo - jluo@mednet.ucla.edu; 
Pam S Kurimoto - pkurimoto@mednet.ucla.edu; Gang Zeng - gzeng@mednet.ucla.edu; Raj K Batra - rbatra@ucla.edu; 
Sherven Sharma - ssharma@mednet.ucla.edu; Steven M Dubinett - sdubinett@mednet.ucla.edu; Jay M Lee* - jaymoonlee@mednet.ucla.edu
* Corresponding author    †Equal contributors
Abstract
Background: Our previous studies have demonstrated that transduction of human dendritic cells
(DC) with adenovirus encoding secondary lymphoid chemokine, CCL21, led to secretion of
biologically active CCL21 without altering DC phenotype or viability. In addition, intratumoral
injections of CCL21-transduced DC into established murine lung tumors resulted in complete
regression and protective anti-tumor immunity. These results have provided the rationale to
generate a clinical grade adenoviral vector encoding CCL-21 for ex vivo transduction of human DC
in order to assess intratumoral administration in late stage human lung cancer.
Methods: In the current study, human monocyte-derived DC were differentiated by exposure to
GM-CSF and IL-4 from cryopreserved mononuclear cells obtained from healthy volunteers.
Transduction with clinical grade adenoviral vector encoding CCL21 (1167 viral particles per cell)
resulted in secretion of CCL21 protein.
Results: CCL21 protein production from transduced DC was detected in supernatants (24–72
hours, 3.5–6.7 ng/4–5 × 106 cells). DC transduced with the clinical grade adenoviral vector were >
88% viable (n = 16), conserved their phenotype and maintained integral biological activities
including dextran uptake, production of immunostimulatory cytokines/chemokines and antigen
presentation. Furthermore, supernatant from CCL21-DC induced the chemotaxis of T2 cells in
vitro.
Conclusion: Viable and biologically active clinical grade CCL21 gene-modified DC can be
generated from cryopreserved PBMC.
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Lung cancer is the leading cause of cancer-related death in
the United States with a 5-year survival rate of only 15%
[1]. Thus, development of new therapeutic strategies is
required. The potential for the immune system to induce
tumor regression has stimulated much research into
development of vaccines to unmask tumor antigens, lead-
ing to a specific host immune response against the tumor
[2]. However, the poor immunogenicity of human lung
cancer due to low expression of major histocompatibility
complex (MHC) antigens, a deficit in transporter-associ-
ated with antigen-processing, and lack of co-stimulatory
molecules, have rendered most of the immunotherapeutic
efforts ineffective [3]. In addition, tumor cell-derived
inhibitory factors and immune suppressive cells such as T
regulatory cells also impede the immune response to
Non-Small Cell Lung Cancer (NSCLC) [4-7].
Dendritic cells (DC) are the most potent antigen present-
ing cells (APC) capable of inducing primary immune
responses [8]. DC express high levels of MHC and costim-
ulatory molecules such as CD40, CD80, and CD86. DC
also produce high levels of cytokines and chemokines,
attracting antigen-specific T cells in vivo. These properties,
combined with the efficient capture of antigens by imma-
ture DC, allow them to efficiently present antigenic pep-
tides and costimulate antigen-specific naïve T cells [8].
Presentation of tumor-associated antigens by DC and
their recognition by cytotoxic T lymphocytes (CTL) play
an important role in the eradication of tumor cells [9].
Based upon the importance of DC in tumor immunity, a
variety of strategies have been used to exploit this cell type
in cancer-immunotherapy [10-12]. Advances in the isola-
tion and in vitro propagation of DC combined with iden-
tification of specific tumor antigens have allowed
initiation of clinical trials testing DC-based vaccines [10-
12]. DC transfer has been demonstrated to be a safe
approach in clinical studies [13-16].
Strategies employing DC in immunotherapy have
included pulsing isolated DC with tumor antigen pep-
tides, apoptotic tumor cells, or tumor lysates ex vivo [17-
19]. DC have also been genetically modified with genes
encoding tumor antigens or immunomodulatory proteins
[20-22]. There is evidence that DC transduced with aden-
oviral vectors (AdV) have prolonged survival and resist-
ance to spontaneous and Fas-mediated cell death [23].
This could result in the improved delivery of immuno-
therapy. AdV transduction itself can also augment the
capacity of DC to induce protective anti-tumor immunity
[24]. In addition, enhanced local and systemic anti-tumor
effects have been demonstrated when AdV transduced DC
expressing cytokine genes have been injected intratumor-
ally [22]. AdV have been utilized to transduce DC because
they efficiently induce strong heterologous gene expres-
sion in these cells [24,25]. Prototypical vectors have now
been extensively used in a variety of contexts [24,25].
CCL21 is a CC chemokine that belongs to a family of pro-
teins involved in leukocyte chemotaxis and activation.
Expressed in high endothelial venules and in T cell zones
of spleen and lymph nodes, CCL21 exerts potent attrac-
tion of naïve T cells and mature DC promoting their co-
localization in secondary lymphoid organs and cognate T
cell activation [26]. We previously reported the potent
anti-tumor properties of CCL21 in murine cancer models
[27-29]. CCL21 has also shown anti-angiogenic activities
in mice, thus strengthening its immunotherapeutic poten-
tial in cancer [30,31].
In our trial, DC will be transduced ex vivo with a replica-
tion incompetent adenovirus (by virtue of critical total
deletions [E1 and partial deletion of E3 regions] in the
adenoviral genome) expressing the CCL21 gene. Because
autologous DC are transduced ex vivo and cells are sedi-
mented, cultured, and extensively washed prior to injec-
tion into patients, this approach will contain the
adenovirus entirely within the DC population so that it is
unable to reproduce or infect adjacent cells. To date, no
generation of replication competent adenovirus (RCA)
has been detected following in vivo vector delivery [25]. In
addition, no proviral integration or gene transfer to the
gonads has been reported with the use of these vectors
[25].
We have hypothesized that intratumoral injection of
CCL21-gene modified DC (CCL21-DC) will stimulate
specific immune responses without excluding patients on
the basis of HLA phenotype or absence of a particular
tumor antigen. CCL21-DC will have access to the entire
repertoire of tumor antigens in situ. In addition, the
CCL21-DC will exploit the professional APC as a vehicle
for cytokine delivery, capitalizing on the capacity of
CCL21 to attract both endogenous host DC and T lym-
phocytes to the tumor site to restore local immune reactiv-
ity. Here we report 1) an effective method for generation
of clinical grade CCL21-DC from cryopreserved mononu-
clear cells (MNC) and 2) CCL21-DC are biologically
active, secreting functional CCL21 capable of inducing
chemotaxis in vitro. Intratumoral administration of clini-
cal grade CCL21-transduced DC will be evaluated in a
phase I clinical trial for late stage Non-Small Cell Lung
Cancer. This therapeutic strategy is hypothesized to
restore tumor antigen presentation and anti-tumor effec-
tor responses, by recruiting APC, T cells, and NK cells due
to the chemotactic effect of CCL21 at the tumor site
[27,28].Page 2 of 17
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Generation of clinical grade AdCCL21
The CCL21 adenoviral construct (AdCCL21), lot#
LO6042006, was manufactured for clinical use by the
Biopharmaceutical Development Program at SAIC-Fred-
erick (Frederick, MD) under FDA good manufacturing
practice (GMP) standards. AdCCL21 is an E1-deleted rep-
lication-deficient serotype 5 adenoviral vector encoding
the full-length cDNA for human CCL21 driven by the
CMV promoter, as previously described [29]. AdCCL21
was originally constructed in our laboratory as follows: A
491 bp insert containing human CCL21 coding sequence
50–463, was amplified from human lymphocyte cDNA
using the following primers: forward 5'-CTTGCAGCT-
GCCCACCTCAC (nucleotides 1–20) and reverse 5'-
TCTCCAGGGCTCCAGGCTGC-3 (nucleotides 491-472).
The CCL21 fragment was cloned into pAC-CMVpLpA to
generate pAC-CMV-CCL21pA. This plasmid was co-trans-
fected with pJM-17, which contains the E1-deleted Ad-
genome, into 293 cells to yield recombinant E1-deleted
adenovirus encoding CCL21 following homologous
recombination. Clones of AdCCL21 were plaque-purified
and viral seed stocks generated in 293 cells, followed by
Cesium Chloride purification, dialysis, and storage at -
80°C as a glycerol stock (10% volume/volume). The titer
of each viral stock was routinely 1011-1012 plaque-forming
units (pfu) by plaque assay on 293 cells. Contamination
with wild type virus or replication competent recom-
binant virus (RCA) was assessed by plaque-forming assay
using the non-permissive A549 lung cancer cell line in
parallel with the permissive 293-cell line. Only lots with
10-4 pfu/ml were utilized for GMP amplification. GMP
AdCCL21 was quantified by absorbance at 260 nm for
particle number and by plaque assay on 293 cells for pfu.
Each lot of virus was tested for presence of bacteria, fun-
gal, mycoplasma and viral contamination, as well as for
endotoxin contamination and RCA. Specifically viral
stocks demonstrating > 1 RCA PFU/109 AdCCL21 PFU
were discarded. An empty vector adenovirus identical to
AdCCL21 but lacking the CCL21 insert (AdCV) was used
as a control where indicated.
Generation of human monocyte-DC
Peripheral blood mononuclear cells (PBMC) were
obtained from leukocyte-enriched buffy coat (leukapher-
esis, LK) from healthy donors (UCLA Blood Bank) under
the approval of UCLA Institute Review Board (IRB).
Informed consent was obtained from each donor. PBMC
were separated by density gradient centrifugation with
Ficoll-Paque™ Plus (Amersham Biosciences, Uppsala,
Sweeden). The light density mononuclear cell fraction
from the 42.5–50% interface was recovered, washed three
times and stored at -80°C in RPMI-1640 (Mediatech Inc.,
Herdon, VA) containing 20% AB serum (Gemini Bio-
Products, Woodlands, CA) and 10% DMSO (Fisher Scien-
tific, Fair Lawn, New Jersey). DC were cryopreserved up to
one month without showing significant changes in viabil-
ity after thawing (data not shown). Cryopreserved MNC
were quickly thawed in a water bath, resuspended at 2 ×
106 cells/ml in serum-free RPMI supplemented with 20
mM HEPES buffer (Mediatech Inc.), 100 units/ml Penicil-
lin-Streptomycin (Invitrogen, Grand Island, NY), and 2
mM L-glutamine (Invitrogen) and allowed to adhere to
tissue culture flasks for 2 h at 37°C. After incubation, non-
adherent cells were discarded or utilized to generate autol-
ogous T cells for the Tetanus Toxoid (TT) assay (described
below). Because DC are loosely adherent cells, they were
harvested by gentle tapping of the flasks and pipetting. For
optimal cell recovery, the flasks were washed twice in
serum-free medium [29]. These cells were cultured for 6
days in complete RPMI with 5% human AB serum, 800 U/
ml GM-CSF (Peprotech Inc., Rocky Hill, NJ), and 400 U/
ml IL-4 (Peprotech). Although laboratory grade GM-CSF
and IL-4 from Preprotech was utilized for these pre-clini-
cal studies, in the phase I clinical trial, clinical grade GM-
CSF and IL-4 cytokines will be used in accordance with
GMP standards and in compliance with FDA require-
ments.
Adenoviral transduction of DC
On day 6 of culture, monocyte-derived DC were harvested
and cell viability was determined by Trypan Blue (Medi-
atech Inc.) exclusion while the viral vectors thawed on ice.
Cells were equilibrated to room temperature (RT) for 15
minutes prior to mock transduction with serum-free cul-
ture medium (DC), or transduction with AdCCL21
(CCL21-DC) or AdCV (CV-DC) where indicated at 1167
viral particles (VP)/cell, equivalent to 100:1 multiplicity
of infection (MOI). Transduction was carried out in serum
free medium by centrifugation [33] using a temperature
controlled microcentrifuge (Eppendorf, Fisher Scientific)
for 2 h at 2000 × g to allow transduction to occur at RT or
37°C [29]. To test whether an immune adjuvant can
improve DC function, 10 μg/ml clinical grade keyhole
limpet hemocyanin (KLH) (BCI-Immunoactivator, Intra-
cel Resources, Frederick, MD) was added to 0, 30, or 100%
of DC, CV-DC, or CCL21-DC prior to centrifugation. After
transduction, cells were washed three times and resus-
pended in RPMI containing 5% AB serum. Cells were
counted and viability was determined by Trypan Blue
exclusion within two hours following transduction. We
expect a maximum delay of two hours prior to intratu-
moral administration due to the safety testing required to
fulfill lot release criteria. Cell viability at two hours follow-
ing adenoviral transduction was confirmed by annexin-V
(AV) and propidium iodide (PI) staining using the AV flu-
orescein isothiocyanin (FITC) kit (Biosource Interna-
tional, Camarillo, CA) in accordance to the
manufacturer's instructions. DC, CCL21-DC, and CV-DCPage 3 of 17
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time course to assess CCL21 production/cell.
Immunophenotypic analysis by flow cytometry
DC, CCL21-DC, and CV-DC were characterized by flow
cytometry after transduction using the following panel of
monoclonal antibodies: HLA-DR-FITC, CD40-phycoery-
trin (PE), CD54-PE, CD80-PE, CD86-PE, and CCR7-PE
(BD Biosciences Pharmingen, San Diego, CA), CD83-
FITC (Coulter Immunology, Hialeah, FL), and appropri-
ate isotype controls (BD Biosciences, La Jolla, CA). Ten
thousand events were acquired within a pre-set DC gate
using a LSR flow cytometer (BD Biosciences, San Jose, CA)
and analyzed using CELLQuest software (BD Biosciences,
San Jose, CA).
To measure dextran (DX) uptake, DC and CCL21-DC
were incubated with FITC-conjugated dextran (DX-FITC)
(Sigma, San Louis, MO, 1 mg/ml) in RPMI with 10% AB
serum for 20 minutes at 37°C. A parallel protocol was
also carried out at 4°C to assess non-specific FITC signals.
After incubation, cells were washed twice in FACS buffer
(PBS (Mediatech Inc.) containing 2% FBS (Gemini) and
incubated with anti-CD86-PE or isotype control for 30–
45 minutes at 4°C. After washing DC were fixed in 400 μl
1% paraformaldehyde (Electron Microscopy Science, Ft.
Washington, PA) and analyzed by flow cytometry. Ten
thousand events were acquired within a pre-set DC gate
using a LSR flow cytometer, as described above.
To evaluate expression of CCR7, T2 cells and day 6 imma-
ture DC (IDC) were incubated with CCR7-PE, appropriate
rat isotype IgG isotype control, or FACS buffer alone for
20 minutes at RT. Cells after washing in FACS buffer were
analyzed using a LSR flow cytometer (BD Biosciences, San
Jose, CA) as described.
Analysis of transduction efficiency
To evaluate the efficiency of gene delivery, we utilized the
reporter gene green fluorescent protein (GFP). Briefly, DC
were transduced with culture medium (DC) or with a rep-
lication deficient adenoviral vector carrying the gene
encoding GFP (Ad-CMV-GFP, Vector Biolabs, Philadel-
phia, PA), driven by the CMV immediate-early promoter
(GFP-DC). Transduction was carried out in serum-free
medium at 1167 VP/cell by the centrifugation method at
RT, as described above. Cells were cultured for 24 or 48 h
prior to analysis of GFP expression. To identify the den-
dritic cell population, both DC and GFP-DC were incu-
bated with CD86 PE antibody or isotype control in FACS
buffer for 20 minutes at RT. Cells were then analyzed for
GFP/CD86 expression by flow cytometry with the LSR
flow cytometer, as described above. Five thousand events
were collected within a pre-set DC gate.
CCL21 ELISA
CCL21 protein concentration in the supernatant of DC,
CV-DC and CCL21-DC was determined by CCL21-Duo-
Set specific ELISA (R&D Systems, Minneapolis, MN) fol-
lowing manufacturer's instructions. Briefly, monoclonal
antibody directed against CCL21 (2 μg/ml) was allowed
to adsorb to a 96-well plate (Costar, Cambridge, MA)
overnight. After three washes in PBS containing 0.05%
Tween-20 (PBS-T), wells were incubated for 1 h at RT with
PBS containing 10% bovine serum albumin (BSA)
(Sigma) to block non-specific binding. On the following
day, CCL21 standard or sample supernatant were added
to the wells and incubated for 2 h at RT. Unbound antigen
was removed by washing with PBS-T and the plate was
incubated with biotinylated anti-CCL21 antibody for 2 h
at RT, washed and incubated with streptavidin-conjugated
HRP (1:200) for 20 minutes in the dark. After washing to
remove unbound reagents, the plate was incubated with
substrate for up to 30 minutes in the dark. The reaction
was stopped by adding 1 M sulfuric acid to the wells and
the optical density at 450 nm was determined using a
microplate reader (Benchmark, Bio-Rad, Hercules, CA).
The sensitivity of this CCL21 assay was 62.5 pg/ml.
IL-12p70, IP-10, and MIG ELISA
To induce IL-12 production, 2.0 × 105 DC, CV-DC, or
CCL21-DC were primed with IFN-γ (50 ng/ml, Peprotech
Inc.) for 2 h and then stimulated with LPS (1 μg/ml,
Sigma), for 48 h. To induce IP-10 and MIG production,
DC, CV-DC, or CCL21-DC were stimulated with LPS (1
μg/ml) for 24 h. IL-12p70 concentration in the cell super-
natant following 48 h stimulation was determined with
the Ready-set-go! ELISA (eBioscience, San Diego, CA) fol-
lowing manufacturer's instructions. The sensitivity of the
IL-12p70 ELISA was 4 pg/ml. IP-10/CXCL10 and MIG/
CXCL9 production were determined 48 h after stimula-
tion with specific ELISA kits (BD Bioscience), following
manufacturer's instructions. The sensitivity of the IP-10/
CXCL10 and MIG/CXCL9 ELISAs were 8 pg/ml and 30 pg/
ml, respectively.
Allogeneic mixed lymphocyte reaction and autologous TT 
presentation assays
To assess the ability of CCL21-DC to induce proliferation
of allogeneic T cells and to evaluate the impact of KLH on
their APC function, we utilized allogeneic T cells as
responder cells in a mixed lymphocyte reaction (MLR)
assay. Briefly, MNC were obtained from PBMC by density
gradient separation as described above. After incubation
for 2 h in tissue culture flasks, non-adherent cells were iso-
lated and plated into a 96-well round-bottom plate at 2.0
× 105 cells/well. KLH (10 μg/ml) was added to 0%, 30%,
or 100% of DC, CV-DC, or CCL21-DC prior to centrufu-
gation, as described in the paragraph of transduction. For
preparation of APC, 0% pulsed or 30–100% pulsed DC,Page 4 of 17
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(50 μg/ml, Sigma, San Louis, MO) for 30 minutes in a
37°C water bath. After three washes all DC samples were
resuspended in RPMI medium containing 10% AB serum
and mixed with responder cells at DC to responder cell
ratios of 1:2, 1:5, or 1:10. T cell proliferation was assessed
with the BrdU Cell Proliferation ELISA kit (Roche Applied
Science, Indianapolis, IN) following manufacturer's
instructions. The incorporation of 5'bromo-2'-deoxyurid-
ine (BrdU) was evaluated by measuring the optical den-
sity (OD) of the replicating responder T cells (405 nm)
after 5 days incubation at 37°C, 5% CO2.
To assess autologous antigen presentation by adenoviral-
transduced DC we employed a standard TT presentation
assay as previously described with some modifications
[32]. Autologous T-cells were generated from non-adher-
ent MNC during preparation of DC. Briefly, non-adherent
MNC were cultured at 1.0 × 106 cells/ml in the presence of
IL-2 (15 U/ml, Dr. James Economou, UCLA, Los Angeles,
CA) for 6 days. KLH (10 μg/ml) was added to 0, 30. or
100% of DC, CV-DC, and CCL21-DC previously treated
with mitomycin C. Autologous T cells were then admixed
to the DC at 10:1 ratio. TT (2 μg/ml, Calbiochem, San
Diego, CA), BSA (Genzyme, Cambridge, MA), or culture
medium alone were added.
T-cell proliferation was assessed by BrdU Cell Prolifera-
tion assay after 5 days incubation at 37°C, 5% CO2, as
described above while effector function was evaluated by
measuring IFN-γ production, after 48 h culture by specific
ELISA (eBioscience, San Diego, CA), following manufac-
turer's instructions. The sensitivity of the IFN-γ ELISA was
4 pg/ml.
Chemotaxis Assay
Chemotaxis assays were performed with T2 cells, a T/B
hybridoma that lacks HLA class II antigen but expresses
HLA.A2 molecules, commonly used to assess specific
cytotoxic T lymphocyte responses. We evaluated the
chemotactic activity of supernatant from DC, CV-DC, and
CCL21-DC as described previously [29]. Briefly, T2 cells
(provided by Peter Cresswell, Yale University School of
Medicine, New Haven, CT) were harvested, counted, and
resuspended in serum-free RPMI medium at 2 × 106 cells/
ml. 100 μl were loaded into the upper chamber of a stand-
ard 24-well plate fitted with 3 μm polycarbonate mem-
brane inserts (Corning Life Science, Corning NY). 400 μl
of supernatant from DC, CV-DC, or CCL21-DC was added
to the lower chamber of each well. 600 ng/ml recom-
binant CCL21 (ED50: 200–600 ng/ml) and 10% AB serum
in RPMI were used as positive and negative controls,
respectively. For total migration, T2 cells were added with-
out the membrane barrier. After incubation for 2 and 1/2
h, migrated cells were recovered from the lower chamber
and quantified by flow cytometry based upon the number
of events per minute collected in a pre-set T2 cell gate. To
evaluate the specific chemotactic activity of CCL21 pro-
duced by CCL21-DC, supernatant from DC, CV-DC,
CCL21-DC or 600 ng/ml recombinant CCL21 protein
were exposed to neutralizing concentrations of anti-
CCL21 antibody (R&D Systems, ND50: 1–4 μg/50 ng
rCCL21) or isotype control (ChromPure Goat IgG, Jack-
son ImmunoResearch Laboratories, West Grove, PA) prior
to loading into the transwell plate and all subsequent
steps were carried out as described above.
Statistical Analysis
The unpaired two-tailed Student's t test and the one-way
ANOVA for multiple groups were used to compare differ-
ences among DC, CV-DC, and CCL21-DC. p values = 0.05
were considered significant.
Results
Generation of DC from cryopreserved human MNC
Our phase I clinical trial entailing two sequential intratu-
moral injections of gene-modified DC will require readily
accessible stocks of autologous MNC. This prompted us to
examine cryopreserved MNC as an optimal source of cells
that would be available in a timely manner. To assess the
feasibility of this approach, a series of pilot experiments
was performed using leukapheresis specimens from
healthy volunteers. Seventeen MNC samples were evalu-
ated after cryopreservation in 10% DMSO and 20% AB
serum in RPMI medium after Ficoll gradient separation.
The in vitro pre-clinical experiments were performed with
MNC that were cryopreserved at -80°C for up to one
month. Although this storage time is beyond the cryop-
reservation time that will be utilized in the clinical trial,
we anticipate initiation of DC culture one week following
the cryopreservation of MNC. Under our experimental
conditions, cryopreservation of MNC up to 30 days did
not result in significant changes in cell viability and yield
(data not shown). As shown in Table 1, the yield for MNC
before cryopreservation averaged 1 × 109± 0.7 cells in 17
experiments. The MNC recovery after thawing averaged
0.66 × 109 ± 0.4 cells with 92.9 ± 4.3% viability, as deter-
mined by Trypan Blue exclusion. DC were obtained from
cryopreserved MNC by culture of adherent monocytes
with laboratory grade GM-CSF and IL-4, as described in
Materials and Methods. After 6 days in culture, the DC yield
from 0.66 × 109 MNC averaged 21.3 × 106 ± 11 (n = 17)
and exhibited an average viability of 95.8 ± 1.7% in 16
independent experiments (Table 1). These results are in
agreement with our previous study [29]. Immunopheno-
typic analysis by flow cytometry using a panel of cell sur-
face markers described previously [29] confirmed that DC
generated in this manner maintained an immature phe-
notype (data not shown).Page 5 of 17
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generates viable biologically active DC
On day 6 of culture DC were transduced with clinical
grade AdCCL21, AdCV, or mock transduced with culture
medium alone, as described [29,32]. To assess the effect of
temperature on DC viability and CCL21 production, pre-
liminary transduction experiments (n = 4) were carried
out in parallel at RT and 37°C. Cell viability and yield
were determined by Trypan Blue exclusion. Transduction
at 37°C and RT resulted in equivalent DC recovery (50.7
± 14% versus 59 ± 0.03%, p > 0.05), but significantly
diminished cell viability (75 ± 0.2% versus 93.6 ± 0.02%,
p = 0.05), respectively (Table 2). Accordingly, all subse-
quent transductions were performed at RT. Cell recovery,
following adenoviral transduction at RT, was 65.9 ± 7.4%
of the initial DC yield in 17 independent experiments,
and the overall viability of CCL21-DC averaged 88 ± 13%
(n = 16), as determined by Trypan Blue exclusion (Table
1). Analysis of apoptosis by AV and PI confirmed these
observations, showing an average viability of 89 ± 5% at
two hours following adenoviral transduction (n = 3, data
not shown).
Transgene expression in CCL21-DC was assessed by meas-
uring CCL21 production in the supernatant of DC, CV-
DC, or CCL21-DC seeded at several densities over a 72 h
time course (Table 3). Production of CCL21 averaged 3.5
± 3.4 ng/5 × 106 cells at 24 h (n = 6), 4.4 ± 2.9 ng/5 × 106
cells at 48 h (n = 7), and 6.7 ± 1.5 ng/4 × 106 cells at 72 h
(n = 4). Maximal CCL21 production was obtained with 1
× 107 CCL21-DC (7.5 ± 2.4 ng at 24 h and 8.7 ± 1.1 ng at
48 h). Neither DC nor CV-DC generated detectable
CCL21 (Table 3). CCL21 protein levels appeared to be
affected by temperature during transduction as demon-
strated by a trend toward higher CCL21 production when
DC were transduced at RT compared to 37°C (1.1 ± 0.7 ng
versus 2.9 ± 2.1 ng at 24 h, and 1.9 ± 1.3 ng versus 3.7 ±
2.5 ng at 48 h, respectively; p > 0.05, Table 2).
Efficiency of adenoviral transduction
The initial attachment of adenovirus to the majority of
human cell types is mediated by its fiber capsid protein,
which binds to the high-affinity Coxsackie-Adenovirus
Receptor (CAR) [25]. MHC molecules may also serve as
receptors for the fiber capsid protein [25]. Alternatively
adenovirus may bind to cells of hematopoietic origin
through αMβ2 integrins [25]. Subsequent internalization
is mediated by αVβ3 or αVβ5 integrins. While immature
DC as well as adenovirus infected-DC or DC matured with
LPS, CD40L, TNF-α, monocyte-conditioned medium
(MCM) and poly (I-C) all lack CAR and αVβ3 integrins,αMβ2 and αVβ5 integrins are expressed at higher levels in
immature DC compared to mature DC [25]. Thus, viral
transduction of human monocyte-derived DC requires
Table 1: Generation of human DC and adenoviral CCL21 transduced DC from cryopreserved MNC.
MNC
Yield
  (BC)
MNC
Recovery
  (AC)
MNC 
Viability
 (AC)
DC
Yield
  (BT)
DC
Viability*
  (BT)
AdCCL21
Recovery
  (AT)
AdCCL21
Viability
  (AT)
N = 17 1 × 109 1 × 109 % 1 × 106 % % %
1.0 ± 0.7 0.66 ± 0.4 92.9 ± 4.3 21.3 ± 11 95.8 ± 1.7 65.9 ± 7.4 88 ± 13%
* N = 16
DC were generated from cryopreserved MNC obtained from leukapheresis (LK) samples under standard culture conditions (6 days culture of 
adherent MNC in GM-CSF and IL-4), as described in Materials and Methods. A summary of the yield, recovery, and viability of MNC is reported 
before cryopreservation (BC), after cryopreservation (AC), before adenoviral transduction (BT), and after adenoviral transduction (AT) with 
AdCCL21 at room temperature. The values express the average ± SD of at least 16 independent experiments.
Table 2: Impact of temperature on AdCCL21 transduction of DC.
AdCCL21-DC
Recovery Viability CCL21
37°C RT 37°C RT 37°C 37°C
ng/1 × 106 ng/1 × 106 ng/1 × 106 Ng/1 × 106
% 24 h 48 24 h 48
50.7 ± 14 59 ± 0.03 75 ± 0.2 *93.6 ± 0.02 1.1 ± 0.7 1.9 ± 1.3 2.9 ± 2.1 3.7 ± 2.5
• p = 0.05
In preliminary experiments (n = 4), the impact of temperature on adenoviral transduction of human DC was evaluated. Cell recovery, viability by 
trypan blue exclusion, and CCL21 production are shown at 37°C and RT.Page 6 of 17
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duction efficiency was assessed by analyzing expression of
a GFP reporter gene measured by flow cytometry. DC were
transduced with an adenovirus expressing GFP under sim-
ilar conditions used for transduction with AdCCL-21. GFP
production measured by flow cytometry revealed 7 and
13% of DC expressed GFP following 24 and 48 hours
from transduction, respectively. The density plots are
shown in Figure 1.
Immature DC phenotype is maintained after AdCCL-21 
transduction
A large body of evidence has emphasized the importance
of DC differentiation in the outcome of adoptive transfer
in cancer patients [10-12]. The effectiveness of DC based
immunotherapy to control human cancer is controversial.
It is especially debated whether DC that infiltrate a tumor
result in tumor-specific tolerance rather than immuniza-
tion [34]. Immature DC appear to be more efficient than
mature DC at antigen internalization and processing and
more effectively augment tumor-specific immune
responses [35]. In our current studies, DC conserved an
immature phenotype after transduction with AdCCL21
(Figure 2). There were no significant differences in cell
surface expression of co-stimulatory molecules or matura-
tion markers (CD40, CD54, CD80, CD83, CD86, and
HLA-DR) between DC (A) and CCL21-DC (B) with the
exception of a modest up-regulation of the CCL21 recep-
tor (CCR7), as we previously observed [29]. CCL21-DC
also retained the ability to internalize dextran comparable
to that of non-transduced DC (Figure 3B and 3D). These
experiments confirmed the immature phenotype of
CCL21-DC as well as their capacity to endocytose antigen,
which has been suggested to be fundamental in the initi-
ation of tumor-specific immune responses [8,9].
CCL21-DC are effective antigen presenting cells
Human DC contain suppressive subsets [36,37] raising
the concern that ex vivo transduction may select for these
suppressive cells and their re-introduction may induce
local immunosuppression or ineffective recruitment of T
cells. Keyhole limpet hemocyanin (KLH) is an immune
adjuvant and hapten carrier which has been used in com-
bination with other immunotherapy strategies. Based on
this function, in the clinical protocol, KLH was planned to
be added as an immune adjuvant to our CCL21 gene
modified DC. However, KLH conjugate vaccines have
shown inconsistent results in clinical trials [38-40]. To
address these concerns and conflicting data on its
immune enhancing function, the biological activity of
CCL21-DC was examined, and the impact of KLH pulsing
was assessed in both allogeneic and autologous settings in
vitro. Because KLH has resulted in variable effects based on
the number of pulsed cells, the impact of KLH on DC APC
capacity was tested by incubating 100%, 30%, and 0% of
DC, CV-DC, and CCL21-DC with KLH. CCL21-DC stimu-
lated T cell proliferation comparable to DC in the alloge-
neic MLR in the presence or absence of KLH (Figure 4A).
However, in autologous TT presentation assays when KLH
was added to CCL21-DC, a significant reduction in IFN-γ
production was noted (Figure 4C). In contrast, it did not
significantly affect DC (Figure 4B) or CV-DC (Figure 4D).
Similarly, we observed impaired proliferation of autolo-
gous T cells (Figure 4E–4F) when either 30 or 100% of DC
(Figure 4E) or CCL21-DC (Figure 4F) were pulsed with
KLH prior to combining with T cells. In this setting, CV-
DC did not show a significant effect in the induction of
autologous T cell proliferation to TT, with or without KLH
(Figure 4G). The background levels of IFN-γ for DC, CV-
DC, and CCL21-DC expressed as range and (mean) were
0 (0), 2242.2–2532 (2523), and 44.2–460.4 (239.5) pg/
ml, respectively. The DC group had IFN-γ levels under the
detection limit of the ELISA assay.
CCL21-DC maintain ability to secrete immune activating 
cytokines and chemokines
We have previously reported that transduction of DC with
laboratory-grade AdCCL21 vector did not impair the
Table 3: CCL21 production.
CCL21 in DC supernatant
 [ng]/cell number
24 h 48 h 72 h
DC CCL21-DC CV-DC DC CCL21-DC CV-DC DC CCL21-DC
Cell number: ×106 Cell number: ×106
1 1 2.5 5 10 1 1 1 2.5 5 10 1 1 4
n = 16 n = 16 n = 9 n = 6 n = 2 n = 6 n = 12 n = 10 n = 7 n = 7 n = 2 n = 6 n = 4 n = 4
ng/cell number ng/cell number ng/cell number
*0.0 2.3 ± 1.9 3.8 ± 2.8 3.5 ± 3.4 7.5 ± 2.4 *0.0 *0.0 3.7 ± 2.4 5.2 ± 2.5 4.4 ± 2.9 8.7 ± 1.1 *0.0 *0.0 6.7 ± 1.5
* Below detection
The capacity of DC to secrete CCL21 was evaluated by ELISA. Mock-transduced DC (DC), CV-DC and CCL21-DC were cultured at the 
concentrations indicated in 1 ml culture medium. The supernatant was analyzed after 24, 48, and 72 h cultures. The concentration of CCL21 is 
expressed in ng per cell number. The values represent the average ± SD of different independent experiments, as indicated.Page 7 of 17
(page number not for citation purposes)
Journal of Translational Medicine 2008, 6:38 http://www.translational-medicine.com/content/6/1/38
Page 8 of 17
(page number not for citation purposes)
Susceptibility of human DC to adenoviral transductionFigure 1
Susceptibility of human DC to adenoviral transduction. DC on day 6 of culture were transduced with an adenovirus 
encoding the marker gene GFP under the same conditions utilized to transduce CCL21-DC. After transduction, DC were cul-
tured up to 48 h. GFP expression was analyzed by flow cytometry at 24 h (A, B) and 48 h culture (C, D), as described in Mate-
rials and Methods. A population of GFP+ CD86+ DC at 24 h (B) and 48 h (D) is shown. Staining with isotype control is indicated 
in A and C. The percentage of GFP+ CD86+ DC is indicated in the upper right corner, and MFI is also reported for D and C. 
The density plots for one representative experiment of four are shown.
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Journal of Translational Medicine 2008, 6:38 http://www.translational-medicine.com/content/6/1/38secretion of IL-12 [29], a critical cytokine for induction of
Th1-mediated anti-tumor immune responses. To further
investigate the immunological properties of CCL21-DC,
IL-12 production was analyzed from these cells upon
stimulation with IFN-γ and LPS. CCL21-DC and CV-DC
maintained the ability to become activated upon stimula-
tion and secrete IL-12 in comparable levels to non-trans-
duced, control DC (Figure 5A).
Given that IP-10/CXCL10 and MIG/CXCL9 are important
for CCL21-DC mediated tumor regression in murine stud-
ies [27,28], we examined whether AdCCL21 transduction
increased the expression of these chemoattractants in
human DC. Our data demonstrate that upon stimulation
with IFN-γ and LPS, CV-DC and CCL21-DC secreted sig-
nificantly higher levels of IP-10/CXCL10 compared to
non-transduced DC, suggesting an adenoviral-mediated
effect on IP-10 production (Figure 5B). Furthermore,
CCL21-DC and CV-DC maintained the ability to become
activated with stimulation and secrete IP-10/CXCL10 in
comparable amounts to that of non-transduced DC (Fig-
ure 5B).
With respect to MIG/CXCL9 production, adenoviral trans-
duction does not impair the ability of DC to secrete MIG
(Figure 5C). CCL21-DC and CV-DC maintained MIG/
CXCL9 levels comparable to that of control DC in both
stimulated and non-stimulated conditions (Figure 5C).
Altogether the in vitro data in human DC support our pre-
vious findings from murine models in which intratumoral
injection of CCL21-DC led to the increased production of
IFN-inducible chemokines and cytokines associated with
tumor regression [27,28].
Supernatants from CCL21-DC stimulate chemotaxis of T2 
cells
Because we hypothesized that CCL21-DC would enhance
chemoattraction of stimulatory T cells and improve the
probability of cognate T cell interaction and cross-presen-
tation, [29] we investigated the ability of CCL21-DC
supernatant to elicit migration of T2 cells. Given the
known experimental variability of using human CD4+ and
CD8+ T cells purified from different individuals, T2 cells
were used due to the known and consistent T2 cell CCR7
expression and the ability to reproducibly culture the cells
in vitro. Supernatant containing as little as 4.8 ng/ml of
CCL21 secreted by at least 2 × 106 CCL21-DC, was suffi-
cient to induce a marked increase in chemotaxis of T2 cells
(One-way ANOVA: p < 0.0001, Figure 6A) compared to
supernatant from non-transduced DC, CV-DC, or diluent
(10% AB) control (Figure 6A and 6B). Recombinant
CCL21 (600 ng/ml) induced chemotaxis was almost com-
pletely abrogated by neutralizing concentrations of anti-
CCL21 antibody but not by the isotype control antibody
DC phenotype is conserved after transduction with AdCCL21Figure 2
DC phenotype is conserved after transduction with AdCCL21. DC (A), and CCL21-DC (B), were analyzed for 
expression of the following surface markers: CD40, CD54, CD80, CD83, CD86, HLA-DR and CCR7, as indicated. Histograms 
show the expression of each surface molecule individually. White lines contour the isotype control. The percentage of positive 
cells and MFI are indicated. A representative experiment of at least three is shown.
33%
MFI: 52
98%
MFI:  211
8%
MFI: 50
10%
MFI: 24
97%
MFI: 260
99%
MFI: 146
4%
MFI: 42
B
A
45%
MFI: 66
98%
MFI:    175
6%
MFI: 67
11%
MFI: 59
96%
MFI: 250
99%
MFI: 184
0.2%
CD40 CD54 CD80 CD83 CD86 HLA-DR CCR7Page 9 of 17
(page number not for citation purposes)
Journal of Translational Medicine 2008, 6:38 http://www.translational-medicine.com/content/6/1/38
Page 10 of 17
(page number not for citation purposes)
Dextran uptake by CCL21-DCFigu e 3
Dextran uptake by CCL21-DC. DC (A and B) and CCL21-DC (C and D) were incubated with DX-FITC at 4°C and 37°C 
for 15 minutes, as described in Materials and Methods. DX expression was analyzed in CD86+ DC. A population of DX+ CD86+ 
obtained at 4°C and at 37°C is shown. Values indicate the percentage and MFI of DX+ CD86+. Density plots of a representative 
experiment of three are shown.
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Journal of Translational Medicine 2008, 6:38 http://www.translational-medicine.com/content/6/1/38(Figure 6B). The chemotactic effect of the CCL21-DC
supernatant was only partially suppressed by neutralizing
concentrations of anti-CCL21 antibody, and continued to
demonstrate pronounced induction of chemotaxis com-
pared to DC (Figure 6B). As shown in figure 6B, in some
experiments, the supernatant from DC transduced with
AdCV induced significant induction of chemotaxis of T2
cells compared to DC alone. While this suggests a vector-
mediated chemotactic effect, CCL21-DC consistently
caused a greater degree of chemotaxis. The CV-DC super-
natant induction of T2 cell chemotaxis was not affected by
the addition of anti-CCL21 antibody (data not shown).
Because CCL21 chemotaxis implies expression of CCR7
on the effector cell surface, the expression of CCR7 in T2
cells was analyzed utilizing immature DC at day 6 of cul-
CCL21-DC are efficient APC in the absence of KLHFigure 4
CCL21-DC are efficient APC in the absence of KLH. (A) Allogeneic MLR: Briefly, culture medium mock-transduced DC 
(DC) and CCL21-DC (AdDC) were analyzed for their ability to induce allogeneic T cell proliferation. The effect of pulsing 
100% (DC KLH 100 and AdDC KLH 100) or 30% of cells (AdDC KLH 30) with 10 μg/ml KLH prior to initiating the MLR assay 
was assessed. After pre-treatment with mitomycin C and KLH, where indicated, DC and CCL21-DC were mixed with alloge-
neic T cells at several ratios, as shown. Cell proliferation was assessed by BrdU incorporation following 5 days incubation at 
37°C. One representative experiment of three is shown. (B-G) Autologous T cell proliferation assay: T cells were cul-
tured for 6 days with IL-2 (15 U/ml) prior to the TT presentation assay. After mitomycin-C treatment and KLH pulsing where 
indicated, DC (B, E), CCL21-DC (C, F), or CV-DC (D, G) were mixed at 1:10 ratio to autologous T cells in the presence of 
TT (2 μg/ml) or BSA (2 μg/ml). In (B-D), IFN-γ production was measured in the cell supernatant collected after 48 hours of 
cell proliferation. The measured values of IFN-γ detected by ELISA were within the linear portion of the IFN-γ concentration 
curve. The concentration of IFN-γ is expressed in pg/ml with basal IFN-γ production subtracted. In (E-G), T cell proliferation 
in response to TT and BSA was measured by BrdU incorporation following 5 days co-culture at 37°C and is expressed as a 
percentage of proliferating cells. One representative experiment of at least three is shown. P value ≤ 0.05 was considered sig-
nificant.
∗ p ≤ 0.04
∗∗ p ≤ 0.001
0
.35
0.7
.05
1.4
 1:10  1:5  1:2
DC KLH-
DC KLH+
AdDC KLH
AdDC KLH
AdDC KLH 
T cells 
DC 
A
DC: T Cell
O
D
:
45
0
n
m
C
D
0
1000
2000
0 30 100 T cells
% 
KLH
IF
N
-
γ
[pg
/m
l]
ns
ns
E
0
40
80
120
0 30 100 T cells
∗
%
pr
ol
ife
ra
tio
n
% 
KLH
∗
BSA
TT
% 
KLH
0
35
70
105
140
0 30 100 T cells
∗∗
%
pr
ol
ife
ra
tio
n
F
0
35
70
105
140
0 30 100 T cells
ns
ns
%
pr
ol
ife
ra
tio
n
% 
KLH
G
% 
KLH
0
1500
3000
0 30 100 T cells
IF
N
-
γ
[pg
/m
l]
% 
KLH
∗
B
0
1000
2000
0 30 100 Tcells
ns
IF
N
-
γ
[pg
/m
l]
BSA
TT
% 
KLHPage 11 of 17
(page number not for citation purposes)
Journal of Translational Medicine 2008, 6:38 http://www.translational-medicine.com/content/6/1/38
Page 12 of 17
(page number not for citation purposes)
CCL21-DC secrete immunostimulatory cytokinesFigure 5
CCL21-DC secrete immunostimulatory cytokines. Human monocyte-derived DC were transduced with culture 
medium, AdCCL21 (1167 VP/cell), or AdCV by the centrifugation method. 2.0 × 105 DC, CCL21-DC, or CV-DC were seeded 
into a 48 well plate in 1 ml of culture medium in the presence or absence of the indicated stimuli. For IL-12 assays, cells were 
stimulated with IFN-γ + LPS, and for IP-10 and MIG assays cells were stimulated with LPS only. The supernatants from stimu-
lated and unstimulated DC were harvested after 48 h culture. IL-12p70 (A), IP-10 (B), and MIG (C) were measured by ELISA. 
Values refer to cytokine concentration expressed in ng/million cells. One representative experiment of four is shown.
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Journal of Translational Medicine 2008, 6:38 http://www.translational-medicine.com/content/6/1/38ture as a negative control. T2 cells expressed high levels of
CCR7 (50%, Figure 6C) compared to immature DC (1%,
Figure 6D).
Discussion
In this report, we describe an effective method for gener-
ating human gene-modified DC for therapeutic use in a
phase I clinical trial of advanced NSCLC. We have opti-
mized a procedure for differentiation of human DC from
Supernatants from CCL21-DC stimulate chemotaxis of T2 cellsFigu e 6
Supernatants from CCL21-DC stimulate chemotaxis of T2 cells. (A) The supernatants from DC, CCL21-DC and 
CV-DC from different individuals (n = 12) were utilized in a standard chemotaxis assay to assess their ability to induce chemo-
taxis of T2 cells. Briefly 2.0 × 105 T2 cells were loaded in the upper chamber of a 24-well transwell apparatus and allowed to 
migrate through a 3 μm insert for 2 and 1/2 h at 37°C. In A, the lower chambers of the transwell had been loaded with the 
supernatant from DC or CCL21-DC (supernatant #1–11) from the same individual, or DC or CV-DC (#12) from the same 
individual, as indicated. Recombinant CCL21 (600 ng/ml) and 10% AB medium were added to the wells as positive and negative 
controls, respectively. A summary of chemotaxis from 12 different samples is shown. The CCL21 protein concentration in ng/
ml is indicated over each column. Migrated cells were analyzed by flow cytometry by counting the number of events per 
minute (expressed as migrated cell number) within a pre-determined T cell gate. One-way ANOVA p < 0.0001. In blocking 
experiments (B), the supernatants from CCL21-DC or recombinant CCL21 were pre-treated with a neutralizing concentra-
tion of anti-CCL21 antibody (1.5 μg/50 ng CCL21) or isotype immunoglobulin, prior loading in the lower chamber of the tran-
swell apparatus. The supernatant from CV-DC and medium containing 10% AB were also assessed. To determine total T2 cell 
migration, T2 cells were loaded without inserts. A representative experiment of a total of seven is shown. The number of 
migrated cells was analyzed by flow cytometry as above, and is expressed as percentage of total T2 cell migration. Asterisks 
denote statistical significance (p < 0.05). The surface expression of CCR7 is analyzed by flow cytometry in T2 cells (C) and in 
immature DC (D) cultured for 6 days in GM-CSF and IL-4. Histograms are shown: dotted lines indicate isotype control, bold 
lines indicate marker expression. The percentage of positive cells and MFI are indicated. A representative experiment of two is 
shown.
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by transduction with a clinical grade E1-deleted, replica-
tion-deficient adenoviral vector, encoding the CCL21
gene. Adenoviral transduction resulted in sufficient quan-
tity of viable immature CCL21-DC for intratumoral
administration. Autologous clinical grade CCL21-DC will
be evaluated in a single center, non-randomized, dose
escalation phase I clinical trial, for subjects with Stage IIIB
and IV NSCLC. The proposed intratumoral injection of
CCL21 gene modified DC is anticipated to promote co-
localization of mature host DC and Th1 lymphocytes at
primary lung tumor, and the use of the tumor as an in vivo
source of antigens will presumably allow the induction of
a specific immune response against a repertoire of tumor
associated antigens (TAA).
We have previously reported our preclinical data on the
use of intratumoral injection of CCL21-DC in murine
models of established lung cancer resulting in tumor erad-
ication by eliciting a systemic anti-tumor immune
response that provided protection against subsequent
challenge with the same tumor cell line [27,28]. Here we
report that 1) human DC can be efficiently transduced ex
vivo with clinical grade adenoviral vector expressing the
CCL21 gene, 2) transduction of DC with AdCCL21 at RT
improved cell viability over that observed after transduc-
tion at 37°C, 3) CCL21-DC demonstrate an immature DC
phenotype with the ability to phagocytose and present
antigens, 4) KLH inhibits the ability of CCL21-DC to
induce T cell proliferation and cytokine production, 5)
CCL21-DC maintain the ability to be activated and pro-
duce IL-12 and transduction does not impair DC genera-
tion of IP-10/CXCL10 and MIG/CXCL9, and 6) CCL21-
DC secrete CCL21 protein within 24 h of transduction
and demonstrate biological activity with induction of
chemotaxis.
Given these ex vivo findings, CCL21-DC upon intra-
tumoral injection/re-introduction into the patient may
demonstrate in vivo ability to internalize and present
tumor associated antigens to host effector cells eliciting a
specific anti-tumoral response, as well as, having the bio-
logical activities specific to CCL21. In murine studies,
CCL21-DC induced tumor regression, stimulated produc-
tion of IFN-γ and the CXC chemokines MIG (CXCL9) and
IP-10 (CXCL10) at the tumor site, and decreased local
concentrations of immunosuppressive inflammatory
mediators including IL-10, PGE2, and TGF-β [27,31].
These changes in cytokine expression were required for an
effective CCL21-DC mediated anti-tumoral response [28].
In vivo depletion of MIG, IP-10, or IFN-γ individually or in
combination reduced the anti-tumor efficacy of CCL21-
DC [27].
The rationale for utilizing CCL21-DC as opposed to direct
injection of AdCCL21 or recombinant CCL21 is derived
from pre-clinical murine studies in which CCL21 admin-
istered as a recombinant protein showed anti-tumor prop-
erties only at very high doses [27,28]. Similarly, injection
of the AdCCL21 vector directly into murine tumors was
only effective at high pfu (greater than 107 VP in 3 sequen-
tial intratumoral injections) [27,28], which is not feasible
for clinical delivery. Therefore, the DC component may be
critical for clinical anti-tumor responses. DC may also
shelter the adenoviral vector from the anti-viral humoral
response of the patient [25]. In previous studies, direct
immunization of mice with recombinant adenovirus
resulted in induction of high titers of neutralizing anti-
bodies and inhibition of CTL response in repeated inocu-
lations [41]. However, DC harboring adenovirus 5, E1-
deleted vectors induce low titers of neutralizing antibod-
ies [25]. The capacity of mice immunized with CCL21-DC
to reject a secondary challenge with tumor cells demon-
strates that CCL21-DC effectively generate a systemic CTL
response and enhance tumor immunogenicity [27,28].
Studies to reveal the molecular mechanism underlying
improved response to CCL21-DC over direct intratumoral
injection of the AdCCL21 viral vector itself or recom-
binant CCL21 are underway in our laboratory.
In the clinical trial, we expect a maximum delay of two
hours prior to intratumoral administration of our final
product (CCL21-DC) into the patient's primary lung can-
cer due to the required safety testing to fulfill lot release
criteria. Our results revealed that the viability of CCL21-
DC at two hours following adenoviral transduction by
trypan blue exclusion (88 ± 13%) and confirmed by
annexin V (AV) staining (89 ± 5%) will successfully meet
the final lot release criteria for cell viability, which is cur-
rently defined to be > 70%.
CCL21-DC exhibited an immature DC phenotype and
intact immune stimulatory capability. Although these DC
features have obvious important implications for intratu-
moral therapy, the addition of immune adjuvants, such as
KLH, have been used in other studies and may further
enhance the anti-tumor effects of vaccination strategies
[38-40]. Interestingly, in this report, our data showed that
the addition of KLH in combination with the CCL21-DC
may have a detrimental effect on elicitation of T cell
responses given that it inhibited the ability of CCL21-DC
to induce T cell proliferation and cytokine production. As
a result, in the proposed clinical trial, KLH was removed
from the protocol.
In support of our preclinical data in which the CCL21-DC
have better anti-tumoral effects relative to AdCCL21 vec-
tor alone or recombinant CCL21 protein, the transduc-
tion of DC with AdCCL21 has the added advantage ofPage 14 of 17
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rus sheltered within the DC. In our study, the superna-
tants from CCL21-DC significantly stimulated T2 cell
chemotaxis. The rationale for utilizing T2 cells to evaluate
the biological efficacy of CCL21-DC supernatants in the in
vitro chemotaxis assays is an attempt to minimize the
known experimental variability of human CD4+ and
CD8+ T cells purified from different individuals, in con-
trast to the reproducible culturing and consistent T2 cell
CCR7 expression of T2 cells. In vivo CD4+ and CD8+ T
cells in fact may exhibit different expression of CCR7
based on their differentiation stage and antigen encounter
[42-44]. Unexpectedly, the chemotactic effect of CCL21-
DC supernatants was only partially inhibited by anti-
CCL21 neutralizing antibody. The control vector trans-
duced DC (CV-DC) in a similar fashion induced the
chemotaxis in a CCL21 independent mechanism, suggest-
ing that additional factors attributed to the adenovirus
itself contributed to stimulation of chemotaxis. Thus,
CCL21-DC induces chemotaxis via CCL21 dependent and
independent mechanisms. While CCL21 is well known to
induce chemotaxis of mature DC and naïve T cells, it has
also been shown to be integral in the co-stimulation of
naïve T cells and Th1 polarization of non-regulatory
CD4+T cells [43]. Furthermore, CD4+CD25+ regulatory T
cells have been shown to be hypo-responsive to CCL21
induced migration [43]. A recent study by Tosello et al.
[44] reported the differential expression of CCR7 in CD4+
CD25+ memory T regulatory cells identifying two popula-
tions: CCR7+ central memory and CCR7- effector memory
T regulatory cells. While both subsets showed similar ex
vivo effector function, only the CCR7- effector memory
population was predominant among T regulatory cells
compared to conventional CD4+ T cells [44]. Therefore,
we anticipate that intratumoral delivery of CCL21-DC will
induce effective chemotaxis in vivo, increase anti-tumor
immune effector cells, and limit T regulatory cell traffick-
ing.
Human lung cancer cells lack critical components of the
antigen processing and presentation pathways required
for initiation of a cell-mediated immune response [45].
Moreover, lung cancer patients have dramatically
decreased numbers of circulating competent DC and their
activity appears to be decreased by soluble factors in the
tumor microenvironment [34,46]. A correlation between
survival and the number of tumor-infiltrating DC has
been reported [47], thus, activating DC at the tumor site
may be an effective approach to treatment of NSCLC. Pro-
viding ex vivo generated DC may be a strategy to overcome
some of these obstacles with the added advantage of DC
cultured in GM-CSF and IL-4 may be more resistant to the
suppressive effects of the tumor microenvironment
[27,28].
Conclusion
Viable and biologically active clinical grade CCL21 gene-
modified DC can be effectively generated from cryopre-
served leukapheresis products. We anticipate that clinical
grade CCL21-DC may be an effective immunotherapeutic
approach in the treatment of NSCLC, utilizing the in vivo
tumor as the source of TAA, and thus eliminating the need
for ex vivo priming with tumor antigens. On the basis of
these pre-clinical findings, an intratumoral administra-
tion of clinical grade CCL21-transduced DC will be evalu-
ated in a phase I clinical trial in late stage NSCLC patients.
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